UK Markets open in 2 hrs 52 mins

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
26.66-1.50 (-5.33%)
At close: 4:59PM CEST
Full screen
Previous close28.16
Bid26.50 x 0
Ask26.90 x 0
Day's range26.36 - 28.40
52-week range22.02 - 109.10
Avg. volume216,041
Market cap931.826M
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Do Options Traders Know Something About Orphazyme (ORPH) Stock We Don't?

    Investors need to pay close attention to Orphazyme (ORPH) stock based on the movements in the options market lately.

  • Motley Fool

    Why Orphazyme Stock Skyrocketed 24.6% Today

    Shares of Orphazyme (NASDAQ: ORPH) skyrocketed 24.6% as of the market close on Wednesday after rising as much as 56.6% earlier in the day. The big gain came after the drugmaker announced that Goldman Sachs (NYSE: GS) temporarily increased its stake to 5.58% on Jun. 16, 2021, but then reduced its position to less than 5% the following day. What does the "major shareholder announcement" made by Orphazyme today mean for investors?

  • Motley Fool

    This Is How You Could Have Anticipated Orphazyme's Implosion

    A lot of everyday investors recently lost a bundle betting that the Food and Drug Administration would approve an experimental drug from Orphazyme (NASDAQ: ORPH). There were reasons to suspect arimoclomol might earn approval to treat a rare life-threatening disease. There were also plenty of reasons to keep your portfolio far away from Orphazyme's attempt to earn approval for its first drug.